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Abstract
Antibiotics are the pillar of surgery from prophylaxis to treatment; any failure is potentially a leading cause for
increased morbidity and mortality. Robust data on the burden of SSI especially those due to antimicrobial
resistance (AMR) show variable rates between countries and geographical regions but accurate estimates of the
incidence of surgical site infections (SSI) due to AMR and its related global economic impact are yet to be
determined. Quantifying the burden of SSI treatment is an incentive to sensitize governments, healthcare systems,
and the society to invest in quality improvement and sustainable development. However in the absence of a
unified epidemiologically sound infection definition of SSI and a well-designed global surveillance system, the end
result is a lack of accurate and reliable data that limits the comparability of estimates between countries and the
possibility of tracking changes to inform healthcare professionals about the appropriateness of implemented
infection prevention and control strategies. This review aims to highlight the reported gaps in surveillance
methods, epidemiologic data, and evidence-based SSI prevention practices and in the methodologies undertaken
for the evaluation of the economic burden of SSI associated with AMR bacteria. If efforts to tackle this problem are
taken in isolation without a global alliance and data is still lacking generalizability and comparability, we may see
the future as a race between the global research efforts for the advancement in surgery and the global alarming
reports of the increased incidence of antimicrobial-resistant pathogens threatening to undermine any achievement.
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Background
Antimicrobial resistance (AMR) threatens to undermine
many advances in the medical field [1] particularly in
surgery. Modern medicine is built on the ability of anti-
biotics to prevent or cure infections [2] but with the
growing incidence of AMR added to a dry pipeline [3],
we may expect the loss of many advantages in surgical
procedures enabled by antimicrobials [4] and a soaring
rate of surgical site infections (SSI). Robust data on the
burden of SSI show variable rates between countries and
geographical regions but accurate estimates of SSI inci-
dence and its related global economic burden are yet to
be determined [5]. Quantifying the costs of SSI can in-
form policy makers about the estimated financial burden
of this complication and the cost-effectiveness of inter-
ventions to reduce it. Literature review shows that in the
absence of a unified epidemiologically sound infection
definition of SSI [6–8] and a well-designed global sur-
veillance system, the end result is a lack of accurate and
reliable data [9–12]. This can limit the comparability of
estimates in terms of rates and costs between countries
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[13, 14], and the possibility of tracking changes to in-
form healthcare professionals about the appropriateness
of implemented infection prevention strategies. The aim
of this review is to highlight the reported gaps in data
gathering methodologies and in the evidence-based
benefit of some of the current infection control and
prevention strategies that limits the possibility of the ac-
curate evaluation of the economic burden of SSI particu-
larly those due to AMR.
Methods
Search strategy and eligibility criteria
Search methods for identification of relevant studies was
conducted on 10, November 2018, using the below four
electronic databases:
 Ovid MEDLINE(R) Epub Ahead of Print, In-Process
and Other Non-Indexed Citations, Ovid MEDLI-
NE(R) Daily and Ovid MEDLINE(R) 1946 to Present
 PubMed http://pubmed.gov
 Embase.com https://www.embase.com/#search
 Cochrane Library www.thecochranelibrary.com
The search strategy principle was based on dividing
the topic into three concepts: (1) economic burden, (2)
surgical site infection, and (3) antimicrobial resistance.
All searches were limited to human and English lan-
guage with no restriction on age or publication date to
ensure that search results include all published articles
pertained to the topic.
Ovid Medline was first searched to identify all the pos-
sible medical subject headings (MeSH) terms with their
corresponding keyword equivalences to increase sensitivity
of the search strategy. This technique utilized the many
search options available for Ovid Medline such as Boolean
operators, truncation, and adjacency searching. The search
strategy combined the three concepts as follows: “costs and
cost analysis”/or cost-benefit analysis/or “cost control”/or
“cost savings”/or “cost of illness”/or health care costs/or dir-
ect service costs/or drug costs/or hospital costs/or *health
expenditures/or exp economics, hospital/or hospital
charges/or exp economics, medical/or fees, medical/or eco-
nomics, pharmaceutical/ OR cost*.mp. OR ((global or eco-
nomic* or financial) adj2 (burden* or impact)).mp. [mp =
title, abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading
word, organism supplementary concept word, protocol
supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms] AND exp Sur-
gical Wound Infection/OR (Surg* adj3 wound* adj3 infec-
tion*).mp. [mp = title, abstract, original title, name of
substance word, subject heading word, floating sub-heading
word, keyword heading word, organism supplementary
concept word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, syn-
onyms] OR ((post-surg* or prosthes* or surg* or postsurg*
or postoper* or post-opera*) adj3 infection*).mp. [mp = title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading
word, organism supplementary concept word, protocol
supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms] AND exp drug
resistance, bacterial/or beta-lactam resistance/or cephalo-
sporin resistance/or penicillin resistance/or ampicillin re-
sistance/or methicillin resistance/or chloramphenicol
resistance/or exp drug resistance, multiple, bacterial/or
kanamycin resistance/or tetracycline resistance/or tri-
methoprim resistance/or vancomycin resistance/ OR (resi-
stan* adj3 antibiotic*).mp. [mp = title, abstract, original title,
name of substance word, subject heading word, floating
sub-heading word, keyword heading word, organism sup-
plementary concept word, protocol supplementary concept
word, rare disease supplementary concept word, unique
identifier, synonyms] OR ((Microbial* or anti-microbial or
antibiotic* or beta-lactam or cephalosporin* or penicillin or
tetracycline or trimethoprim or vancomycin or fluoroqui-
nolone*or quinolone* or carbapenem* or teicoplanin* or
aminoglycoside* or colistin*) adj3 resistan*).mp. [mp = title,
abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading
word, organism supplementary concept word, protocol
supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms].
After finalizing Medline strategy, the search terms
were appropriately adapted into the three other data-
bases. The obtained results were screened and studies
were excluded if their primary objective was not solely
the evaluation of the burden of surgical site infection.
Further reading and screening articles showed that it is
not possible to quantify the burden of SSI if the accuracy
and reliability of data is questionable due to gaps in sur-
veillance and epidemiology methods and it was also not
possible to discuss AMR prevention without further
highlighting the gaps in current SSI infection and pre-
vention practices. Further search included articles
through gray literature and organizational publications
(i.e. National Institute for Health and Care Excellence,
Centers for Disease Control and Prevention, World
Health Organization and European Center of Disease
Prevention and Control). Further studies were identified
by examining the reference lists of all included articles
(Fig. 1).
Results
Economic burden of SSI
Surgical site infection is the leading cause of substantial
burden worldwide [15–19]. It is the third most costly
type of healthcare-acquired infection (HAI) with an
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estimated cost of US $20,785 per patient case [20]. The
current annual costs to the health-care system amounted
to billions of US$ has doubled since 2005 [20, 21]. The
economic burden of SSIs is associated with direct medical
costs related to prolonged hospitalization [22–25], intensive
care units (ICU) stay [26], reoperation [27], surgical tech-
niques [28], hospital readmission [29, 30], and consumption
of medical resources [31]. These are attributed to investiga-
tion, diagnostic tests [13], medical staff namely skilled sur-
geon’s fees [28], operative costs [13], antibiotic prophylaxis
[6], and treatment costs [11, 22–25, 32], in addition to the
for-profit or not-profit nature of healthcare system services
[28]. Indirect costs attributable to SSI are the increased risk
of morbidity and mortality estimated two to eleven times
greater in patients with SSI compared with non-infected
patients [33–36], the decrease in the patient quality of life
[37], absenteeism from work and loss of earnings during re-
covery [13]. Several studies consistently demonstrated the
profound impact of SSI on the length of hospital stay [9,
11, 18, 25, 27, 29, 38, 39] with the number of hospitalization
days varying per country, type of surgery [13], patient age
and co-morbidities [40] whether associated with nosoco-
mial infection [18] in addition to the presence of a
prosthetic implant [41, 42]. The majority of the studies con-
sidered the increased costs of SSI relative to non-infected
patients [23, 27, 30, 37, 43, 44] but very few [36] have evalu-
ated the costs associated with infections due to resistant
compared with susceptible bacteria. SSI due to AMR are
difficult to treat and may represent a great challenge com-
plicating further the clinical and economic outcomes of the
disease [36, 45–52].
The concept of economic burden of SSI from different
perspectives
In times where healthcare expenditure continues to
climb and resources are limited, cost savings and shifting
resources use from treating toward preventing infection,
is an important goal. Current strategies, focusing only
on the costs of SSI to improve the quality of care, are
providing a myopic view of the real cost associated with
infection in general and with SSI in particular. That is the
wider cost of not having an effective antibiotic to pre-
vent or treat the infection. Studies have demonstrated
that the concept of cost savings varies according to the
chosen perspective.
Fig. 1 Search strategy and eligibility criteria
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From the economists perspective, the costs associated
with SSI treatment are viewed as an “opportunity cost”
that deprive hospitals from using the allocated financial re-
sources elsewhere [13] (i.e., investing in quality improve-
ment plans). However, recent publications have challenged
this paradigm [53, 54]. Rauh et al. claims that quality im-
provement may enhance hospitals profitability but will not
drastically solve the fixed hospital costs dilemma [54]. It is
the rigid cost structure that is relatively insensitive to
changes in resources use, so clinical improvement will
generate additional capacity to treat more patients but will
not lead to bottom line savings [55]. So basically, under-
standing the cost layers in the healthcare system will pro-
vide management with a framework to target changes.
From the hospital perspective, taking preventive mea-
sures to avoid SSI and reduce readmission rate and hos-
pital length of stay is thought to be a “top priority” [31],
ultimately resulting in cost savings. Some studies show
that accounting for these proxy to demonstrate cost sav-
ings is “illusory” [55, 56], may lead to bias and result in
disputed outcomes [55, 57].
Furthermore, since the cost-effectiveness of some of
these proposed measures is not yet demonstrated [58–60],
then the hospitals may be allocating a higher budget and
making less profit to potentially avoid these complications
in the absence of incentives proving their clinical effective-
ness. Therefore, cost savings through preventing SSI may
be questionable unless the undertaken measures to fulfill
this goal are evidence-based and part of the hospital stra-
tegic quality improvement plan.
From the payer perspective, there is a high financial
benefit when SSI are avoided because they are linked to
higher average payment to hospitals [31]. Variable strat-
egies have been undertaken to give the hospitals the drive
needed to reduce SSI. However, the current system of re-
imbursement may provide a financial disincentive to their
reduction [61]. Certain strategies like financial penalties or
excluding HAI in tariff have backfired through hospitals
underreporting and reluctance in openly sharing SSI inci-
dence results openly. Rather, it is proposed that it would
be more productive to develop a system based on trans-
parent reporting, financial reward, innovation, and inciting
physician’s engagement [62]. Additional suggestions would
be payers bundling the average costs of complications into
the base diagnosis-related group (DRG) payment or limit-
ing the hospital ability to recode retrospectively into
higher paying DRG which may give the hospitals the in-
centive needed to avoid complications [61].
From a societal perspective, the magnitude of the eco-
nomic burden of SSI might not be known if ascertain-
ment is left solely to the index hospital’s information
systems [13]. In monetary terms, cost savings from this
perspective means avoiding indirect costs incurred by
the patient through absenteeism from work and out -of-
pocket payments to treat SSI infections. It also means
the cost of avoiding pain and suffering and the negative
effect on the quality -of -life but most importantly it
means the cost needed to prevent antimicrobial resist-
ance associated with SSI.
Methods for evaluating the economic burden of SSI
The global variability of healthcare systems, financial struc-
tures, currencies, local epidemiologic data, and resistance
patterns have limited the generalizability and the compar-
ability of the economic evidence between countries [13].
This has highlighted the urgent need for high-quality stud-
ies using a standardized methodology for the evaluation of
the economic burden of SSI [6, 63]. Literature review has
shown that the major limitations in these studies are mainly
related to (1) the uses of different definitions to classify SSI
[7] and to the inability to follow-up with patients long
enough post-surgical discharge [64]. Across the literature,
the characteristics of population and subgroups analysis
may differ. (2) Stratifying patients is crucial especially by
age groups and underlying co-morbidities. Most of the
studies rarely consider the surgical cases complications in
pediatric population, known to be at higher risk of SSI and
have different pathogens patterns [6]. Limitations in the
methods of economic evaluation may also be related to
(3) the location and settings were the study was conducted
(i.e. Studies grouped into the same surgical specialty may
not be comparable due to differences in operating theater
conditions and surgical procedures [13, 63]). Some studies
assigned the development of SSI to multiple or unspecified
surgeries which can be a source of bias, limiting the com-
parability of data. In addition, it is highly recommended to
account for differences in the effectiveness of antimicrobial
stewardship programs, preoperative prophylactic strategies,
treatment failure [63], infection control practices, and anti-
microbial susceptibility testing across countries and set-
tings. (4) Description of the study perspective and how it
relates to the allocated costs is important. Literature review
shows that studies were undertaken from different perspec-
tives mainly the hospital and the payer perspective, ac-
counting for the direct costs of treating SSI, and rarely
considered the costs incurred from the patient perspective.
Most importantly, some studies did not explicitly state the
perspective and none have evaluated the wider impact on
society and included the indirect costs, e.g. costs of pain,
suffering, and loss of productivity [65]. (5) Comparators in-
cluded across the literature considered patients with SSI
versus uninfected patients [66]. It is argued that such com-
parison may lead to the overestimation of costs [67] mainly
because the treatment of infection will increase the costs
[57] especially if the causative agent is an AMR and patients
may be at higher risks of additional co-morbidities leading
logically to an extra incurred cost [67]. In order to
minimize bias in quantifying the burden of SSI treatment, it
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is suggested to compare cases of SSI due to resistant- with
cases due to susceptible -bacteria. (6) It is also noted that
the time horizon is not considered consistently and may
not capture all data. Since most cases of SSI occur post-
discharge, some patients are not readmitted to the indicated
hospital, or there may be difficulty following up the patient
especially in LMICs [68]. (7) Discount rates if warranted
and relevant cost components were either omitted or not
clearly stated, including the incremental cost, discounting,
and the results of sensitivity analysis [6, 63]. (8) Description
of outcomes as the measure of benefit in the economic
evaluation and their relevance to the type of analysis per-
formed is highly recommended. The three most common
economic evaluation tools are cost-effectiveness analysis,
cost–utility analysis, and cost–benefit analysis; they differ in
the nature of the measured consequences. Of note, the
cost-of-illness analysis does not measure the outcomes but
only the related costs of the disease. This type of study is
considered a baseline to inform health-economic analysis.
Literature review shows the uses of different study designs
[53, 65, 69], and inappropriate allocated type of health-
economic analysis. (9) Sources of data and methodology of
data collection can be an important source of bias especially
if not explicity described, if single-centered and collected
retrospectively from hospital databases regardless if gener-
ated from high or LMICS. (10) SSI is a time-dependent ex-
posure. However, time-dependent bias has been recognized
as a problem in analyzing HAI infection data, and the ap-
propriate type of analysis is subject of debate [70]. (11) A
detailed description of the analytical method should be
clearly stated including methodology of dealing with
skewed, missing, or censored data, adjustments made,
handling population heterogeneity and uncertainty, in
addition to the assumptions and the model used if applic-
able [71].
Reported gaps in SSI data gathering
Gaps in epidemiologic data
SSI is considered the second most common type of HAI in
Europe and the USA. In low-to-middle-income countries
(LMICs), data shows that one in ten people undergoing sur-
gery acquire HAI [68, 72, 73]. It is estimated that SSI rates
in developed countries vary between 1.2 and 5.2% while in
developing countries, the pooled incidence is 11.8% per 100
surgical procedures [12]. Current figures may likely be
underestimated because most data arise from hospital set-
tings while around half of SSI cases become evident post-
discharge [74]. In-hospital SSI estimates may not be reliable
even in high-income countries since very few hospitals can
afford to allocate time, budget, and human resources or
because of the limited expertise in study design, data collec-
tion, or interpretation [9–11]. Other causes may be due to
the fact that current surveillance reports may lack
generalizability and comparability of data, they may be non-
comprehensive to all types of surgeries, and not specific to
the classification of infection (e.g., clean, contaminated,
dirty). If SSI rates are to serve as a quality indicator and
comparison benchmark for healthcare facilities, countries,
and the public [5], there is an ongoing need for well-
designed global surveillance system and high-quality studies
that use a common approach to SSI definition, patient se-
lection, determination of endpoints, and follow-up [13].
The need for standardized definitions of SSI
Standardizing the SSI definition is a challenge that requires
a multidisciplinary expertise and allocation of time and
resources. A systematic review by Bruce et al. identified 41
different definitions for SSI addressed in the literature
among which very few were standardized and set by multi-
disciplinary groups [7, 75, 76]. SSI definitions are based on
multiple factors such as site of infection and type of
incision, presence of purulent discharge, clinical signs and
symptoms, or physician diagnosis in a specific surveillance
population, and laboratory results [16]. The Center of Dis-
ease Control and Prevention (CDC) [8, 77] refers SSI to “an
infection that occurs after surgery in the part of the body
where the surgery took place. Surgical site infections can
sometimes be superficial infections involving the skin only.
Other surgical site infections are more serious and can in-
volve tissues under the skin, organs, or implanted material”;
other definition by the ECDC [78] consider SSI as “an in-
fection that occurs within 30 days after the operation and
involves the skin and subcutaneous tissue of the incision
(superficial incisional) and/or the deep soft tissue (for ex-
ample, fascia, muscle) of the incision (deep incisional) and/
or any part of the anatomy (for example, organs and spaces)
other than the incision that was opened or manipulated
during an operation (organ/space)”. In limited resources
settings, the World Health Organization (WHO) [68] rec-
ommends to define SSI based on clinical signs and symp-
toms given the lack of quality microbiology laboratory
support. The variability of SSI definitions and the methods
used for the detection of infection should be accounted for
when comparing evidence from different studies. Inconsist-
ent application of definitions across all sites and time pe-
riods can generate poor data resulting from SSI surveillance
[68, 79] which can potentially lead to underreporting of the
disease, and invalid inter-country and inter-network infec-
tion rate comparisons and benchmarking [6, 79].
Gaps in SSI surveillance methodology
The need to develop a surveillance program for SSI is well
recognized since the late 1960s . This proposition is
credited to Dr. Cruse and his team who argued that retro-
spective data are not reliable, because hospital records are
inaccurate for studies of SSI. They proposed a prospective
wound surveillance [74, 80] currently considered the gold
standard for an efficient surveillance strategy [81]. In
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developed countries, SSI surveillance is either mandatory or
voluntary-based while in developing countries, data is
scarce, primarily single-centered, hospital-based, especially
in Asia, South America, and Africa [33]. Hospital-based
surveillance is likely to underestimate the true rate of SSI, a
problem that is exacerbated by the increasing trend toward
shorter lengths of post-operative hospital stay and 1-day
surgery [82]. Implementing a system that enables the iden-
tification of SSI cases post-discharge generates high-quality
data; however, there are many challenges and practical diffi-
culties in the community settings limiting the accurate and
reliable identification of SSI cases and thus the generation
of valid data [83]. On the other hand, a network-based sur-
veillance may lead to various impact on SSI rates. Some
studies report a positive outcome after participation in a
network [82, 84, 85] while others report no changes [86]. It
is argued that bias related to network-based surveillance
methodologies can be avoided by adding hospitals to the
network according to their year of participation [87] or
stratifying SSI rates by surveillance time- to -operation in
consecutive 1-year periods using the first year of surveil-
lance as a reference [88]. However, till date, there is no gold
standard method for post-discharge surveillance [89] nor
an ideal method of surveillance design or implementation
[90] nor a universally adopted cut-off length of surveillance.
The CDC suggests a shortened period of 90 days post-
discharge in order to avoid delayed feedback; however, this
protocol is not always accounted for and depends on the
type of surgical procedure being studied [91]. Choosing the
outcome indicator is also subject to debate. Literature re-
view shows that the most common outcome indicator is
the cumulative SSI incidence also known as SSI rate. Some
authors consider that reporting SSI using prevalence
methods is considered less reliable and argue that the inci-
dence density of in-hospital SSI is a more suitable choice by
taking into account different lengths of hospital stay
and different post-discharge surveillance methods.
Accounting for the variations in case-mix and stratifica-
tion of patient characteristics, choosing the appropriate
risk-adjustment index is essential in order to improve
the validity of comparisons [92, 93]. Reliable microbiol-
ogy support is an essential component of SSI surveil-
lance. However, clinical diagnosis of SSI can be made
without microbiological confirmation, an approach that
may be considered acceptable in countries with limited
resources; it should be noted that this method can give
an estimate of the overall rates of SSI in general but
not the specific rates of bacterial resistance associated
with SSI especially those occurring in LMICs, an area
considered highly endemic [94].
SSI due to antimicrobial resistant pathogens
Resistance patterns of bacteria associated with SSI vary
globally depending on the region, local epidemiology
reports, and methodology of susceptibility testing. SSI
treatment is becoming very complex and challenging
[45, 46] due to bacterial resistance. The mainstay of
adequate therapy is the early diagnosis of SSI and micro-
biological diagnostics [91]. Identification of the resist-
ance patterns among SSI cases is crucial [95, 96] in
order to avoid the misuse and abuse of antibiotics
especially broad-spectrum drugs adding to the economic
burden of the disease [56]. Studies have shown differ-
ences in the virulence of bacteria among outpatient
compared with inpatient settings where inpatients popu-
lation had a higher number of resistant organisms
causing SSI [46, 97]. Most of the data comes from high-
income countries where multidrug-resistant Escherichia
coli and Staphylococcus aureus [46] are the most fre-
quently reported isolates. Some studies report high inci-
dence of gram-negative bacteria depending on the type
of surgery being studied while other highlight the in-
creased incidence of MRSA isolated from surgical sites
[98]. However, despite scarce reports on the rates of re-
sistant bacteria causing SSI especially from LMICs, stud-
ies evaluating the economic burden of SSI related to
these pathogens are needed [6].
Effectiveness of infection control and prevention
strategies
The ultimate aim of preventing SSIs is to secure patient
safety while decreasing the rate and burden of infection
[99, 100] especially those due to AMR bacteria. Recently,
the CDC [101], the WHO [12, 99], and the American Col-
lege of Surgeons and Surgical Infection Society [102] pub-
lished their guidelines for the prevention of SSI. These
guidelines are intended to provide updated evidence-
based recommendations from targeted systematic review
[101] of the best evidence to prevent SSI. As a result, sur-
geons are given guidance about strong recommendations
practices while they are left with no recommendations if
the level of evidence is low to very low-quality with uncer-
tain trade-offs between the benefits and harms [103].
These guidelines should be implemented as part of a com-
prehensive surgical quality improvement program using
multimodal strategies [9, 64, 99, 100]. An unresolved
issue/no recommendation level highlights the current gaps
in research and the need for powered, well-designed ran-
domized trials that addresses these issues especially in
LMICs [64, 100, 101, 103]. This also means that some of
the current practices considered an integrated part of the
quality improvement plan may be consuming tremendous
amount of time and resources potentially without
evidence-based benefit adding to the burden of the SSI.
Research gaps in the prevention of SSIs also extend be-
yond the current heterogeneous practices to a more cru-
cial serious threat that is the prevention of SSI due to
AMR bacteria [94].
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Discussion
Quantifying the economic burden of SSI is difficult and
challenging in the absence of validated method to avoid
bias and enhance generalizability of findings [104]. Lit-
erature search showed that most articles evaluating the
costs of SSI considered the payer or hospital perspectives
and compared SSI cases with no infection cases with
very few exceptions considering SSI due to resistant bac-
teria [16, 36, 105, 106]. In an era where antibiotic resist-
ance is affecting the world sustainable development
[107], the optimal way to avoid bias in quantifying the
burden of SSI is to consider the bigger impact of SSI
due to resistant—compared with SSI due to suscep-
tible—bacteria from the society perspective taking into
account that infection is a time-dependent variable [69].
Estimating the burden of SSI is not only a budget issue
or a public health issue, it is a global need to assess how
health resources are spent, and to points out if expendi-
tures are justified in terms of efficiency and effectiveness
and most importantly how they are directly or indirectly
affecting the world sustainable development. Literature
search showed that we should start with continuous
consistent global surveillance (Table 1), with a unified
definition of SSI to allow comparability and extrapola-
tion of findings. It may seem that this is the work of re-
searchers and epidemiologists or may only be the
government responsibility through health policies but in
fact there are multiple other stakeholders including sur-
geons, other healthcare workers, the patient and family,
and more broader, the society. It all starts in the operat-
ing room and depends on the type of surgery, the surgi-
cal procedure and on the effectiveness of practices to
prevent SSI. It also extends to the applicability of infec-
tion control and prevention strategies during hospital
stay and for a specific period after discharge, on the pa-
tient and family knowledge about the risks of SSI and re-
lated prevention strategies.
Based on this review and the results of included stud-
ies, the following actions are recommended to tackle the
reported gaps in:
1. The methodology of SSI surveillance (Table 1) [5,
68, 78, 90]
a. Set a unified comprehensive definition of SSI
b. Design a standardized SSI surveillance system
that allows global, regional, and national
benchmark and comparability of data
c. Determine the incentives and support needed
for a valid data gathering
d. Set a focused priority list of resistant pathogens
causing SSI as guidance for research studies
e. Assess and address the challenges of
appropriate and reliable data gathering
methodology in developed as well as in
developing countries and evaluate the
barriers and limitations in resources and
expertise
f. Report consistently the surveillance data
gathered in-hospitals and post-discharge
g. Suggest and validate open access training
materials for accurate data gathering, data entry
and analysis
2. The methodology of quantifying the burden of SSI
(Table 2) [15, 68]
a. Design high-quality prospective studies to quan-
tify the burden of SSI and consider infections
due to resistant -compared with susceptible-
bacteria pathogens.
b. Consider matched cohorts and take into
account the site and type and modality of
surgical intervention, the classification of
surgery, patient factors (i.e., age, underlying co-
morbidities), surgical theater factors and IPS,
physician factors, and follow-up period.
c. Choose an appropriate methodology to evaluate
the economic burden of SSI and take into
account confounding factors and biases
especially time dependence bias [69]
d. Address the wider impact and consider the
perspective of society
3. The research studies of SSI (Table 2) [15]
a. Tackle the economic and clinical impact of SSI
and SSI prevention strategies with a special
focus on pediatric and geriatric population
b. Fill the research gaps in LMICs taking into
consideration the resources limitation and explore
the gaps and the barriers in data extrapolation and
comparability in high income countries
c. Consider evaluating the cost-effectiveness and
the cost-utility of SSI prevention strategies
Conclusions
In an era of increased pressure for cost containment
and alarming reports of the projected impact of
AMR, quantifying the burden of SSI due to resistant
bacteria can inform the governments and decision
makers about the magnitude of the disease and pro-
vide incentives to invest in preventive strategies that
tackles both the inpatient and outpatient settings.
However, if efforts to reduce SSI are taken in isola-
tion without a global alliance and data is still lacking
generalizability and comparability, we may see the fu-
ture as a race between the global research efforts for
the advancement in surgery and the global alarming
reports of the increased incidence of antimicrobial re-
sistant pathogens threatening to undermine any
achievement.
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Table 1 Review of the suggested protocols for surgical site infection
Core value Dedication, commitment, consistency, and leadership support
Fundamental The same definition of SSI should be used across all sites and time periods
In LMICs: definitions based on clinical signs and symptoms should be prioritized
Stakeholders Government, society, patient, patient family, hospitals, and payers
Surveillance methods Direct, prospective in-hospital and post hospital discharge
In LMICs: possible mobile phone contact
Surveillance duration Continuous surveillance of SSI rates per patient case and per surgical procedure
In LMICs: At least 3 to 6 month
Patient follow –up In-hospital
30-days or up to 90 days post-discharge
One year for surgical procedures that requires an implant
Surveillance team Core team: surgical staff, theater staff and IPC staff
Surveillance team qualifications Highly trained on surveillance method
High level of competency for data management and analysis
Basic background in epidemiology, microbiology, and communicable diseases
Surveillance protocol Detailed written plan including elements of the surveillance process integrated
into a comprehensive infection control risk assessment process
Training materials and information sheets
Detailed method of data validation
Constant intensity of surveillance for an area of interest
Data Detailed patient inclusion and exclusion criteria
Stratifying by patient characteristicsa
Date of onset of infection, isolate results, antibiotic code, antimicrobial susceptibility
testing results; microorganisms and antimicrobial resistance data
Data sources Medical records and human resources records
Financial services and Information services
Ancillary service reports; admission diagnoses reports; administrative/management
reports; public health reports; marketing reports
Surgical database
Other sources: quality/utilization management; risk management; community agencies;
occupational/employee health; communication with caregivers
Data entry Preferably electronic support previously tested for accuracy and reliability
Data collection tools Hospital size, type, location, code, surveillance period start
Post-discharge surveillance: READM; REPSURG; REPGP; REPPAT; ICSURG; ICGP; CPAT
Data analysis Present risk-adjusted SSI incidence; crude estimates; NNIS risk index
Ethical issues Patient, hospital, and unit confidentiality
A pre-discharge patient education and engagement with a signed assent
READM = detection at readmission (= passive post-discharge surveillance): patient is readmitted with SSI, often because of the SSI; REPSURG = reporting on
surgeon’s initiative: surgeon actively reports post-discharge infections detected at outpatient clinic or private clinic follow-up to the hospital surveillance staff, e.g.,
using standardized forms, web-based system, e-mail, or telephone; REPGP = reporting on GP’s initiative: general practitioner (GP) reports post-discharge infections
detected at follow-up consultation to the hospital surveillance staff, e.g., using standardized forms, web-based system, e-mail or telephone; REPPAT = reporting on
patient’s initiative: e.g., form send to hospital surveillance staff; ICSURG = obtained by IC staff from surgeon: the hospital surveillance staff—usually infection
control (IC) staff—obtains information from surgeon using telephone, additional questionnaire, visit to surgeon or patient chart review; ICGP = obtained by IC staff
from GP: hospital surveillance staff obtains information from general practitioner using telephone, additional questionnaire or visit; CPAT = obtained by IC staff
from patient: hospital surveillance staff obtains information from patient using telephone or additional questionnaire References: [5, 68, 78, 90]
aAge; sex; type of surgical procedure; whether elective or emergency surgery; the American Society of Anesthesiologists (ASA) score; timing and choice of
antimicrobial prophylaxis; preoperative skin preparation; other indicators, e.g., protocol for intensive perioperative blood glucose control used and blood glucose
levels monitored; implant in place; multiple operations during the same session or not; endoscopic procedure or not; duration of the operation; and wound
contamination class; site of infection and type of SSI (superficial, deep, organ/space); number of OR openings; microbiology confirmation; outcome from hospital;
patient discharge date; readmission date
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Table 2 Gaps in research for the prevention of SSI
Main topic Recommended
Parenteral antimicrobial prophylaxis Selection of the most appropriate antibiotic according specific
to different surgical procedure especially cardiac and vascular
surgeries
The optimal timing of preoperative SAP according specific to
different surgical procedure [15]
The optimal doses, intra-operative dose adjustments and
re-dosing protocols of antibiotics [15]
The effect of weight-adjusted parenteral antimicrobial prophylaxis
dosing on the risk of SSI [15]
The effect of prolonged antibiotic prophylaxis on the
microbiome
Nonparenteral antimicrobial prophylaxis The effect of intra-operative antimicrobial irrigation
Comparisons between the most commonly-used irrigation
practices
Evaluation of the practices of soaking prosthetic devices in
antimicrobial solutions before implantation for the prevention
of SSI
Assessment of the need for applying an autologous platelet-rich
plasma for the prevention of SSI [15]
Evaluation of the use of Antimicrobial-coated sutures for the prevention
of SSI [15]
Comparison between the antimicrobial coated and non-coated
sutures using the same type of suture material, including non-
absorbable sutures
Evaluation of the use of antimicrobial dressings applied to surgical
incisions after primary closure in the operating room for the prevention
of SSI [15]
Investigation of potential effects and adverse effects related to the use
silver-containing dressings especially in orthopedic and cardiac surgery
Comparison between the uses of opaque dressings and transparent
ones in terms of postoperative visual examination and the duration of keeping
the primary dressing in place
Glycemic control The optimal hemoglobin A1C target levels for the prevention of SSI in
patients with and without diabetes [15]
The optimal route of insulin administration and the optimal timing and
duration of perioperative glycemic control [15]
The optimal duration of continued postoperative glucose control
Comparison of different blood glucose target levels to define the optimal
level with minimum risk of hypoglycemia
Normothermia Comparison and selection of the optimal warming device and the proper
timing and duration of warming practices
The optimal timing, duration and limit of normothermia [15] and determine
the target temperature
Perioperative oxygenation The administration of increased FIO2 via endotracheal intubation during only
the intra-operative period in patients with normal pulmonary function
undergoing general anesthesia [15]
The optimal target level, duration, and delivery method of FIO2 for the
prevention of SSI [15]
The administration of increased FIO2 via face mask during the perioperative
period in patients with normal pulmonary function undergoing general
anesthesia without endotracheal intubation or neuraxial anesthesia [15]
The administration of increased FIO2 via face mask or nasal cannula during
only the postoperative period in patients with normal pulmonary
function [15]
The optimal target level, duration, and delivery method of Fio2 [15]
Investigations of the benefit of post-extubation hyperoxemia,
including different durations, concentrations and oxygen
administration routes
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Table 2 Gaps in research for the prevention of SSI (Continued)
Main topic Recommended
The effect of hyperoxygenation on the incidence of SSI
The consequences of the use of a higher concentration of narcotics,
hypnotics or inhalational agents or muscle relaxants
Antiseptic prophylaxis The optimal timing of the preoperative shower or bath, the total
number of soap or antiseptic agent applications, or the use of
chlorhexidine gluconate washcloths [15]
Cost-effectiveness analyses to examine timing and duration of bathing
in different types of surgery and wound classes, especially in LMICs
Comparison of different antiseptic agents to each other and to plain soap
for preoperative bathing
Assessment of the effect of soap or antiseptics on the skin microbiome
Evaluation of the effect of chlorhexidine gluconate (CHG) in reducing SSI and
their cost implications
The need for a antimicrobial sealant immediately after intraoperative skin
preparation [15]
The need of plastic adhesive drapes with or without antimicrobial properties [15]
The practice intraoperative irrigation of deep or subcutaneous tissues with
aqueous iodophor solution [15]
The practice of intraperitoneal lavage with aqueous iodophor solution in
contaminated or dirty abdominal procedures [15]
The repeat application of antiseptic agents to the patient’s skin immediately before
closing the surgical incision [15]
Comparison of specific preparations containing CHG, PVP-I and other antiseptics in
alcohol-based and other solutions
Blood transfusion The effect of blood transfusions on the risk of SSI in prosthetic joint
arthroplasty
Perioperative discontinuation of Immunosuppressive agents The effect of systemic corticosteroid or other immunosuppressive therapies on
the risk of SSI in prosthetic joint arthroplasty [15]
The optimal time between discontinuation of immunosuppressive
The optimal dose of the various immunosuppressive therapy agents including new
ones with regards to the SSI rate
The use and timing of preoperative intra-articular corticosteroid injection on the in
cidence of SSI in prosthetic joint arthroplasty [15]
Anticoagulation The use of venous thromboembolism prophylaxis on the incidence of SSI in
prosthetic joint arthroplasty [15]
Orthopedic surgical space suit The use of orthopedic space suits or the health care personnel who should wear
them for the prevention of SSI in prosthetic joint arthroplasty [15]
Biofilm The cement modifications and the prevention of biofilm formation or SSI in
prosthetic joint arthroplasty [15]
Prosthesis modifications for the prevention of biofilm formation or SSI in prosthetic
joint arthroplasty [15]
The uses of vaccines for the prevention of biofilm formation or SSI in prosthetic
joint arthroplasty [15]
Decolonization with mupirocin for the prevention of Staphylococcus
aureus infection in nasal carriers
Determination of the surgical patient population that should undergo screening for
S. aureus carriage
Determination of the timing and duration of mupirocin administration and bathing
in surgical patients
Investigating other agents for the decolonization of nasal S. aureus carriers
scheduled for surgery
Screening for extended-spectrum beta-lactamase colonization and the
impact on surgical antibiotic prophylaxis
Investigations of the tailored modification of SAP in areas with a high prevalence
of ESBL-producing Enterobacteriacae, including patients known
to be colonized with ESBL, is more effective in reducing the risk
of SSI than no modification of the standard prophylaxis
The effect of a routine screening for ESBL prior to surgery on the
widespread use of broad-spectrum antibiotics pre-surgery in ESBL-
colonized patients and the emergence of resistance in gram negative
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Table 2 Gaps in research for the prevention of SSI (Continued)
Main topic Recommended
bacteria, especially carbapenem-resistant Enterobacteriacae
Mechanical bowel preparation and the use of oral antibiotics Comparison of oral antibiotics and adequate intravenous prophylactic
antibiotics vs. adequate intravenous prophylactic antibiotics only RCT
focusing on laparoscopic procedures
Hair removal Evaluation of the optimal timing and the most appropriate setting
(ward vs. home) for the hair removal procedure when it is considered
necessary by the surgeon
The best and most acceptable methods of hair removal in settings with
limited resources need to be investigated, including low-cost solutions
Test evidence-based procedures on how to decontaminate clippers
Studies with a focus on the use of clippers in LMICs
Surgical hand preparation Comparison of the effectiveness of various antiseptic products with sustained
activity to reduce SSI vs. ABHR or antimicrobial soap with no sustained effect
Assessment of the interaction between products used for surgical hand preparation
and the different types of surgical gloves, in relation to SSI outcome
Nutritional support The impact of nutritional support in LMICs
Investigating the benefit of other nutritional elements (for example, iron, zinc) and
vitamins
The optimal timing and duration of the administration of nutritional support in
relation to the time of surgery
Maintenance of adequate circulating volume control/normovolemia Identification of the most accurate and least invasive method of measuring
normovolemia and assess its influence with regard to tissue oxygenation and
normothermia
Drapes and gowns Investigating the use of sterile disposable compared to sterile reusable drapes and
surgical gowns in terms of SSI prevention
Types of materials (including permeable and impermeable materials) and address
environmental concerns (water, energy, laundry, waste, etc.)
Investigating whether drapes should be changed during the operation and if this
measure has an effect on SSI rates
Investigating the potential benefits of these products
Wound protector devices Comparison of single with double-ring WP devices and reporting adverse events re
lated to the intervention
Prophylactic negative pressure wound therapy Investigating the use of pNPWT for SSI prevention
The identification the cost effectiveness of pNPWT in different groups of patients
including those undergoing contaminated and dirty procedures
The identification the optimal level of negative pressure and duration of
application
Use of surgical gloves Investigating the effectiveness of double-gloving compared to the use of a single
pair of gloves would be welcome on SSI
Comparing different types of gloving to address the question of the
optimal type of gloves to be used
Valuation whether a change of gloves during the operation is more effective in
reducing the risk of SSI than no change of gloves are needed, including an
assessment of the criteria for changing gloves during the surgical procedure
Changing of surgical instruments Investigating the change of instruments prior to wound closure
Laminar airflow ventilation systems in the context of operating room
ventilation
The effects of laminar flow in reducing the SSI rate, require a massive investment
with a high sample size to have enough power to see a difference
The impact of fans/cooling devices and natural ventilation on the SSI rate compared
to conventional ventilation in order to evaluate whether these systems might be an
alternative in resource-limited countries
Optimal timing for wound drain removal The optimal timing for drain removal especially in orthopedic joint
replacement and cardiac surgery and the effect on SSI
Investigating the benefit of early drain removal in pediatric
populations and among neonates
LMICs low–middle-income countries, SAP surgical antibiotic prophylaxis, PK pharmacokinetic, PD pharmacodynamics, FIO2 fraction of inspired oxygen,
CHG chlorhexidine gluconate (CHG), ESBL extended spectrum beta-lactamase, MBP mechanical bowel production, ABHR alcohol-based hand rub, pNPWT
prophylactic negative pressure wound therapy, OR operating room
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